Poster
Mobocertinib (TAK-788) in EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: treatment beyond progressive disease in platinum-pretreated patients with and without intracranial progressive disease
Author
Pasi A Jänne
Condition
metastatic non–small cell lung cancer
Source url
s3://convoke-optic-posters/2024-05-10/Janne et al. Mobocertinib in EGFR Exon20+ metastatic NSCLC. Poster presented at ASCO 2022.pdf
7 organizations
1 product
Product
MobocertinibOrganization
Dana-Farber Cancer Institute, Boston, MA, USAOrganization
Emory University, Atlanta, GA, USAOrganization
Shanghai Pulmonary Hospital, Shanghai, China